Human Liver Microphysiological System for Studying Acute and Chronic Drug-Induced Liver Toxicity

With safety concerns being the major cause for failures in phases 1/2 clinical trials, it’s essential to develop more predictive models within preclinical drug discovery to improve data translatability.

In this webinar, CN Bio Senior Scientist Dr. Ovidiu Novac will discuss how a human liver microphysiological system (MPS), or Liver-on-a-chip, can be used to understand the causality and mechanistic aspects of drug-induced liver injury (DILI).

Ovidiu will discuss how his team validated the MPS using a broad set of mild to severely hepatotoxic compounds and how the MPS delivered novel insights not previously seen in vitro.

Attend this webinar to:

Discover how the liver MPS can be used to detect mild through to severe DILI toxicants
Understand how MPS can be used to generate mechanistic signatures of hepatotoxicity
Enable your scientists to reduce drug attrition in the early phases of clinical trials

Attend this webinar to:

Discover how the liver MPS can be used to detect mild through to severe DILI toxicants
Learn more about generating multiparameter EC50 curves from six toxicological end points
Understand how MPS can be used to generate mechanistic signatures of hepatotoxicity
See how easy it is to adapt the model to assess inflammatory-mediated toxicity
Detect clinical markers that are notoriously difficult to detect in vitro (e.g., AST/ALT)
Enable your scientists to reduce drug attrition in the early phases of clinical trials